A B-Cell-Targeted Approach to Steroid-Resistant Nephrotic Syndrome in Children (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0821; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Prior to rituximab infusion, all 31 patients received steroids, 25 (81%) tacrolimus, 19 (61%) mycophenolate mofetil, 9 (29%) cyclosporin, and 9 (29%) cyclophosphamide. Conclusion In a real-world cohort of pediatric patients with biopsy-proven podocytopathies, rituximab therapy was associated with high rates of remission, particularly in steroid-responsive disease, while nonresponse was confined to steroid-resistant patients. These findings suggest that B-cell-directed therapy may have an important role in selected pediatric nephrotic syndrome populations and provide a strong rationale for prospective, phenotype-stratified clinical trials."
Clinical • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Renal Disease
|
|
Haley Elizabeth Moss; Tanmaya Ravi; Ambarish Athavale
|